ProfileGDS5678 / 1418062_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 90% 89% 87% 87% 89% 89% 88% 88% 89% 88% 86% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8640388
GSM967853U87-EV human glioblastoma xenograft - Control 27.2442190
GSM967854U87-EV human glioblastoma xenograft - Control 37.0352889
GSM967855U87-EV human glioblastoma xenograft - Control 46.819187
GSM967856U87-EV human glioblastoma xenograft - Control 56.7094487
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8750789
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8465389
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.833388
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8438688
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0266889
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8480488
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5474486
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8413988
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9053288